Biogen Inc. vs Merck & Company, Inc.
A head-to-head of Biogen Inc. (BIIB) and Merck & Company, Inc. (MRK) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | BIIB | MRK |
|---|---|---|
| Market Cap | $30.41B | $314.90B |
| P/E (TTM) | 22.10 | 35.92 |
| Forward P/E | 12.20 | 12.87 |
| P/S | 2.90 | 4.40 |
| P/B | 1.62 | 9.93 |
| EV/EBITDA | 8.26 | 17.18 |
| Dividend Yield | — | 1.80% |
| Profit Margin | 13.81% | 13.59% |
| Gross Margin | 75.69% | 74.80% |
| Operating Margin | 24.96% | 34.01% |
| Revenue Growth (YoY) | +1.93% | +4.87% |
| FCF Yield | 8.07% | 4.88% |
| Debt / Equity | 33.72 | 106.94 |
| Current Ratio | 3.06 | 1.30 |
Which is better: Biogen Inc. or Merck & Company, Inc.?
- ✓Larger by market cap: Merck & Company, Inc.
- ✓Cheaper valuation (lower P/E): Biogen Inc.
- ✓More profitable (net margin): Biogen Inc.
- ✓Faster revenue growth: Merck & Company, Inc.
- ✓Higher free-cash-flow yield: Biogen Inc.
Across 12 available metrics, Biogen Inc. leads 10–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Biogen Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.